顕性肝性脳症治療の世界市場 - 2023年～2030年

概要

世界の顕性肝性脳症治療市場は、そのダイナミクスに影響を与える様々な要因によって、長年にわたって著しい成長と変容を遂げてきました。肝不全および/または肝動脈シャントによって引き起こされる正常な脳機能の症候性障害は、顕性肝性脳症として知られています。肝硬変患者の約40％が治療中に経験します。40％の患者では、顕性脳症の初発は再発を意味します。

特に新興経済諸国における政府投資と研究開発は、緩下剤や抗生物質のような新規医薬品の利用を引き続き促進し、世界の顕性肝性脳症治療市場を押し上げると思われます。それぞれの革新的な治療法は複数の研究者によって開発され、現在試験中です。

市場促進要因：市場抑制要因

資金調達と買収の増加

新興経済諸国は、高額の投資、所得水準、インフラ整備を原動力として、ヘルスケア分野の改善において急速な成長を遂げています。いくつかの国では、研究の高まりにより、顕性肝性脳症治療に対する大きな需要が発生しています。さまざまな国間での共同研究、買収、技術的進歩を伴う製品発売は、市場の成長を促進する重要な要因です。

2023年3月28日、Umecrine Cognition社は3億1,600万クローネの新規資金を獲得し、同社の医薬品開発イニシアチブは前進しています。認知障害を治療するため、Umecrine Cognition社は新しいクラスの医薬品を開発しています。現在、肝性脳症（HE；肝性昏睡）と原発性胆汁性胆管炎（PBC）の治療薬として開発されているゴレキサノロンは、ユメクリン社の最先端医薬品候補です。

これらの重篤な疾患は脳機能に影響を及ぼすため、強い倦怠感、集中力の低下、運動協調性の低下などの症状が現れます。これまでの臨床試験や前臨床試験の結果は、ゴレキサノロンがこのような脳機能の低下を補うことができるという考えを圧倒的に支持しています。

さらに、いくつかの研究開発目的のために、高度な研究レベルの新しい技術の利用が増加しています。顕性肝性脳症患者の増加と革新的な治療開発のための研究の増加は、顕性肝性脳症治療市場の成長を促進する主な要因です。

顕性肝性脳症治療薬に関連する副作用

リファキシミンは全身に吸収されないため、忍容性は良好です。対照試験における有害事象の脱落率はリファキシミン、プラセボともに0.4％でした。食欲不振、下痢、味覚低下、鼻腔不快感はまれな副作用です。リファキシミン患者は、吐き気、胃のむかつき、倦怠感、めまい、末梢浮腫、筋痙攣などの薬物による悪影響を経験する可能性があります。

長期使用はまた、細菌または真菌の超感染に関連しています。広範に使用されているにもかかわらず、リファキシミンが血清酵素値を上昇させたり、臨床的に明らかな肝障害を引き起こすという証拠はほとんどないです。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 資金調達と企業買収の増加
    • 技術的進歩と開発の高まり
  • 抑制要因
    • 顕性肝性脳症治療薬に伴う副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• SWOT分析
• 特許分析
• ロシア・ウクライナ戦争の影響分析
• DMI意見

第6章 COVID-19分析

第7章 薬剤別

• 緩下剤
  • ラクツロース
  • ラクチトール
• 抗生物質
  • リファキシミン（キシファキサン）
• L-オルニチンL-アスパラギン酸塩
• プロバイオティクスまたはプレバイオティクス
• 分岐鎖アミノ酸

第8章 投与経路別

• 経口
• 直腸
• その他

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他のアジア太平洋
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• Axcella Therapeutics
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• COSMO PHARMACEUTICALS
• Umecrine Cognition AB
• Salix Pharmaceuticals（Bausch Health Companies Inc.）
• ASKA Pharmaceutical Holdings Co., Ltd.
• Lupin
• Norgine
• Teva Pharmaceutical Industries Ltd.
• Fresenius Kabi Austria GmbH
• Fengchen Group Co.,Ltd

第13章 付録

Overview

The global overt hepatic encephalopathy treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. The symptomatic impairment of normal brain function brought on by hepatic failure and/or portosystemic shunting is known as overt hepatic encephalopathy. About 40% of cirrhotic patients experience it during their therapeutic treatment. In 40% of individuals, a first incidence of overt encephalopathy signals recurrence.

Government investments and research, particularly in developing economies, will continue to drive utilization of novel medicines like laxatives or antibiotics and boost the global overt hepatic encephalopathy treatment market. The respective innovative treatment are being developed by several researchers and currently are under trials.

Market Dynamics: Drivers & Restraints

Growing funding and acquisitions

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for overt hepatic encephalopathy treatment owing to the rising research. Various collaborations, acquisitions and product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.

On March 28, 2023, the company's medication development initiatives are moving forward thanks to fresh finance of SEK 31,6 million obtained by Umecrine Cognition. To treat cognitive disorders, Umecrine Cognition is creating a new class of medicines. Currently being developed for the treatment of individuals with hepatic encephalopathy (HE; liver coma) and primary biliary cholangitis (PBC), golexanolone is the company's most advanced medication candidate.

Due to the severe diseases' impact on brain function, symptoms such intense weariness, trouble concentrating, and poor motor coordination develop. Previous clinical or pre-clinical study findings overwhelmingly support the idea that golexanolone can compensate for such impaired brain function.

Furthermore, the rising utilization of novel technology with high level of research for the several development purposes. Rising overt hepatic encephalopathy cases and increasing research for innovative treatment development will be a major factor driving the growth of the overt hepatic encephalopathy treatment market.

Side effects associated with the overt hepatic encephalopathy medications

Because rifaximin is not absorbed systemically, it is well tolerated. The dropout rates for adverse events in controlled trials were 0.4% for both rifaximin and the placebo. Anorexia, diarrhea, taste loss, and nasal passage discomfort are rare side effects. Rifaximin patients may experience negative medication effects such as nausea, stomach upset, weariness, dizziness, peripheral edema, and muscular spasms.

Long-term use has also been linked to bacterial or fungal super-infections. Despite its extensive usage, there is minimal proof that rifaximin increases serum enzyme levels or causes clinically obvious liver damage.

Segment Analysis

The global overt hepatic encephalopathy treatment market is segmented based on medications, route of administration, distribution channel and region.

Antibiotics segment accounted for approximately 39% of market share

A non-absorbable oral antibiotic is rifaximin. In addition to treating travelers' diarrhea brought on by noninvasive Escherichia coli strains, rifaximin is also used to treat overt hepatic encephalopathy in adults and manage irritable bowel syndrome associated diarrhea. Rifaximin is active against a wide range of anaerobic and aerobic gram-positive and gram-negative bacteria.

Due to its non-absorbable nature, this antibiotic is mostly used to treat infections that affect the gastrointestinal tract. Rifaximin is non-absorbable, which enables it to accumulate to high concentrations in the gastrointestinal lumen where it can treat a variety of gastrointestinal illnesses without causing systemic side effects. Bacterial transformation or drug resistance to rifaximin are extremely rare in extra-intestinal microorganisms.

On June 22, 2023, an application for a partial change to the production and distribution authorization for RIFXIMA TABLETS (rifaximin) has been submitted by ASKA Pharmaceutical Co., Ltd., a wholly owned subsidiary of ASKA Pharmaceutical Holdings Co., Ltd., for an increase in dosage and administration to pediatric patients for the treatment of hyperammonemia in hepatic encephalopathy.

Geographical Penetration

North America accounted for around 35% of market share in 2022

Due to the rising need for overt hepatic encephalopathy treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for overt hepatic encephalopathy treatment.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different types of medicines, and increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of overt hepatic encephalopathy treatment market share of this region. The market in this area is growing as people become more aware of various novel approved medicines. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global overt hepatic encephalopathy treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for overt hepatic encephalopathy treatment in the U.S. United States have been proactive in executing several initiatives or researches, stimulating overt hepatic encephalopathy treatment demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global overt hepatic encephalopathy treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various medicines, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical and pharmaceutical industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for overt hepatic encephalopathy treatment. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global overt hepatic encephalopathy treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for inovative treatment.

Key Developments

• On June 19, 2023, the XIFAXAN (rifaximin) data was provided by Bausch Health Companies Inc. and Salix Pharmaceuticals, its gastrointestinal division, and was chosen for inclusion in the Cirrhosis and its consequences session at the 2023 European Association for the Study of the Liver (EASL) Congress.
• On June 30, 2021, AXA1665, the Axcella's multi-targeted oral item candidate for lowering risk of persistent overt hepatic encephalopathy (OHE), has entered its initial clinical sites and screened patients for its worldwide Phase 2 clinical trial. Axcella is a biotechnology clinical-stage company that has invented a new approach for treating complex diseases and enhance health utilizing endogenous metabolic modulator (EMM) compositions.

Competitive Landscape

The major global players in the market include: Axcella Therapeutics, COSMO PHARMACEUTICALS, Umecrine Cognition AB, Salix Pharmaceuticals (Bausch Health Companies Inc.), ASKA Pharmaceutical Holdings Co., Ltd., Lupin, Norgine, Teva Pharmaceutical Industries Ltd., Fresenius Kabi Austria GmbH and Fengchen Group Co.,Ltd.

Why Purchase the Report?

• To visualize the global overt hepatic encephalopathy treatment market segmentation based on medications, route of administration, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of overt hepatic encephalopathy treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global overt hepatic encephalopathy treatment market report would provide approximately 61 tables, 59 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Medications
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Growing funding and acquisitions
    • 4.1.1.2. Rising technological advancements and developments
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with the overt hepatic encephalopathy medications
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. SWOT Analysis
• 5.6. Patent Analysis
• 5.7. Russia-Ukraine War Impact Analysis
• 5.8. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Medications

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 7.1.2. Market Attractiveness Index, By Medications
• 7.2. Laxatives*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Lactulose
  • 7.2.4. Lactitol
• 7.3. Antibiotics
  • 7.3.1. Rifaximin (Xifaxan)
• 7.4. L-ornithine L-aspartate
• 7.5. Probiotics or Prebiotics
• 7.6. Branched Chain Amino Acids

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Oral *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Rectal
• 8.4. Others

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Axcella Therapeutics*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. COSMO PHARMACEUTICALS
• 12.3. Umecrine Cognition AB
• 12.4. Salix Pharmaceuticals (Bausch Health Companies Inc.)
• 12.5. ASKA Pharmaceutical Holdings Co., Ltd.
• 12.6. Lupin
• 12.7. Norgine
• 12.8. Teva Pharmaceutical Industries Ltd.
• 12.9. Fresenius Kabi Austria GmbH
• 12.10. Fengchen Group Co.,Ltd

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us